McClure Matthew W. 4
4 · Aligos Therapeutics, Inc. · Filed Jul 11, 2022
Insider Transaction Report
Form 4
McClure Matthew W.
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-07-07+46,000→ 46,000 totalExercise: $1.41Exp: 2032-07-07→ Common Stock (46,000 underlying)
Footnotes (1)
- [F1]1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 7, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.